Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...

Computational research conducted by scientists from Washington University in St. Louis shows that GLP-1 agonists can have ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

The funding, which follows the $176 million the government awarded Moderna in June 2024, aims to get mRNA vaccines ready ...

In this bonus episode, BioSpace's vice president of marketing ⁠Chantal Dresner⁠ and careers editor ⁠Angela Gabriel⁠ take a ...

There are currently no treatments available for celiac disease beyond a gluten-free diet. Several late-phase companies aim to ...

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...